Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

被引:102
作者
Bai, Fan [1 ]
Li, Gang Gang [1 ]
Liu, Qingmin [1 ]
Niu, Xinwu [1 ]
Li, Ruilian [1 ]
Ma, Huiqun [1 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China
关键词
INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; PLACEBO-CONTROLLED TRIAL; TO-SEVERE PSORIASIS; DOUBLE-BLIND; PHASE-III; ANTI-INTERLEUKIN-17-RECEPTOR ANTIBODY; ADALIMUMAB; USABILITY;
D O I
10.1155/2019/2546161
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The role of interleukin-12 (IL-12), interleukin-23 (IL-23), and interleukin-17 (IL-17) has been recognized in psoriasis pathogenesis, and new drugs targeting this axis have already been developed which may provide a new therapeutic approach for patients with moderate to severe psoriasis. Objective. To compare the direct and indirect evidences of the efficacy and safety of brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab in the short-term treatment of moderate to severe plaque psoriasis using network meta-analysis (NMA). Methods. A comprehensive literature search was performed in PubMed, EMBASE, and Cochrane Central Register of Controlled Trials for the available relevant studies. NMA was conducted by Stata 15.0 software using relative risks (RR) with 95% confidence interval to assess the clinical effectiveness and safety. Ranked the efficacy and safety for each drug accordance with the surface under the cumulative ranking curve (SUCRA). Results. This meta-analysis included 28 studies. All the interventions performed better than placebo in short-term achievement. Based on the result of SUCRA, ixekizumab 80 mg every 2 weeks ranked the highest in short-term achievement of PASI 75 (SUCRA = 93.0%). Brodalumab 210 mg ranked the highest in short-term achievement of PASI 100 (SUCRA = 85.0%). Secukinumab 300 mg ranked the highest in short-term achievement of sPGA 0/1 or IGA 0/1 or PGA 0/1 (SUCRA = 98.1%). In terms of having a risk of adverse events, the rates were higher in brodalumab, secukinumab, ixekizumab, and ustekinumab 45 mg compared with placebo. Ixekizumab 80 mg every 4 weeks ranked the highest in the risk of adverse events during short-term treatment (SUCRA = 4.5%). Guselkumab 50 mg ranked the highest in the risk of serious adverse events during short-term treatment (SUCRA = 25.9%). Ixekizumab 80 mg every 4 weeks ranked the highest in the risk of discontinuations due to adverse events during short-ter treatment (SUCRA = 10.7%). Conclusions. IL-17, IL-12/23, and IL-23 inhibitors had high efficacy in the achievement of PASI 75, PASI 100, and sPGA 0/1 or IGA 0/1 or PGA 0/1 in moderate to severe plaque psoriasis after 12 or 16 weeks of treatment. IL-17 inhibitors showed superior efficacy. However, its clinical safety was poor. Risankizumab appeared to have relatively high efficacy and low risk. The clinical tolerance of other biological agents needs to be further observed.
引用
收藏
页数:25
相关论文
共 38 条
[1]   A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis [J].
Bilal, Jawad ;
Berlinberg, Adam ;
Bhattacharjee, Sandipan ;
Trost, Jaren ;
Bin Riaz, Irbaz ;
Kurtzman, Drew J. B. .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (06) :569-578
[2]   Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE) [J].
Blauvelt, A. ;
Prinz, J. C. ;
Gottlieb, A. B. ;
Kingo, K. ;
Sofen, H. ;
Ruer-Mulard, M. ;
Singh, V. ;
Pathan, R. ;
Papavassilis, C. ;
Cooper, S. .
BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (02) :484-493
[3]   Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial [J].
Blauvelt, Andrew ;
Papp, Kim A. ;
Griffiths, Christopher E. M. ;
Randazzo, Bruce ;
Wasfi, Yasmine ;
Shen, Yaung-Kaung ;
Li, Shu ;
Kimball, Alexa B. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (03) :405-417
[4]   Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials [J].
Cui, Lian ;
Chen, Rongfen ;
Subedi, Smriti ;
Yu, Qian ;
Gong, Yu ;
Chen, Zeyu ;
Shi, Yuling .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2018, 62 :46-58
[5]   The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis [J].
Di Cesare, Antonella ;
Di Meglio, Paola ;
Nestle, Frank O. .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 (06) :1339-1350
[6]  
Famenini S, 2013, J DRUGS DERMATOL, V12, P317
[7]   Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis [J].
Gordon, K. B. ;
Blauvelt, A. ;
Papp, K. A. ;
Langley, R. G. ;
Luger, T. ;
Ohtsuki, M. ;
Reich, K. ;
Amato, D. ;
Ball, S. G. ;
Braun, D. K. ;
Cameron, G. S. ;
Erickson, J. ;
Konrad, R. J. ;
Muram, T. M. ;
Nickoloff, B. J. ;
Osuntokun, O. O. ;
Secrest, R. J. ;
Zhao, F. ;
Mallbris, L. ;
Leonardi, C. L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04) :345-356
[8]   Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials [J].
Gordon, Kenneth B. ;
Strober, Bruce ;
Lebwohl, Mark ;
Augustin, Matthias ;
Blauvelt, Andrew ;
Poulin, Yves ;
Papp, Kim A. ;
Sofen, Howard ;
Puig, Lluis ;
Foley, Peter ;
Ohtsuki, Mamitaro ;
Flack, Mary ;
Geng, Ziqian ;
Gu, Yihua ;
Valdes, Joaquin M. ;
Thompson, Elizabeth H. Z. ;
Bachelez, Herve .
LANCET, 2018, 392 (10148) :650-661
[9]   A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis [J].
Gordon, Kenneth B. ;
Duffin, Kristina Callis ;
Bissonnette, Robert ;
Prinz, Joerg C. ;
Wasfi, Yasmine ;
Li, Shu ;
Shen, Yaung-Kaung ;
Szapary, Philippe ;
Randazzo, Bruce ;
Reich, Kristian .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :136-144
[10]   Psoriasis [J].
Greb, Jacqueline E. ;
Goldminz, Ari M. ;
Elder, James T. ;
Lebwohl, Mark G. ;
Gladman, DafnaD. ;
Wu, Jashin J. ;
Mehta, Nehal N. ;
Finlay, Andrew Y. ;
Gottlieb, Alice B. .
NATURE REVIEWS DISEASE PRIMERS, 2016, 2